Esanex
About:
Esanex is a drug development company that focuses on advancing its highly selective and orally active Hsp90 inhibitors.
Top Investors: Intersouth Partners
Description:
Esanex is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors. SNX-5422, created from a novel chemical scaffold that is unique in the Hsp90 field, has shown outstanding pre-clinical activity in a number of tumor models and is currently completing Phase 1 trials.
Total Funding Amount:
$15M
Headquarters Location:
Indianapolis, Indiana, United States
Founded Date:
2011-01-01
Founders:
Number of Employees:
Last Funding Date:
2012-06-13
IPO Status:
Private
Industries:
© 2025 bioDAO.ai